Your browser doesn't support javascript.
loading
OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program.
Aurora, S K; Dodick, D W; Diener, H-C; DeGryse, R E; Turkel, C C; Lipton, R B; Silberstein, S D.
Affiliation
  • Aurora SK; Stanford University, Stanford, CA, USA.
Acta Neurol Scand ; 129(1): 61-70, 2014 Jan.
Article in En | MEDLINE | ID: mdl-24107267
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Botulinum Toxins, Type A / Migraine Disorders Type of study: Clinical_trials Aspects: Patient_preference Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: Acta Neurol Scand Year: 2014 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Botulinum Toxins, Type A / Migraine Disorders Type of study: Clinical_trials Aspects: Patient_preference Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: Acta Neurol Scand Year: 2014 Document type: Article Affiliation country: Country of publication: